Hey Hesk - you can find that sort of information in company announcements but it's always generic - it think they last one just says late 2017/ early 2018 - from what I understand they were aiming for middle of this year but on the advice of some people who may or may not have joined the Board they are doing some things that will increase the appeal to pharma to partner once the pack is presented.
Regarding MACD - they can mess with your head if you try to predict them - ie can leg lower before a steep rise an cross over.
I'm keen to see whether MYC is announced in the CRUK grand challenge again -
https://www.cancerresearchuk.org/fu...earch/grand-challenge-award/challenge6?wssl=1
This did not get funded last year but I believe there was interest in forming a syndicate with Laura S & Gerard E if it came up again this year. The new challenges are announced next week.
https://www.cancerresearchuk.org/fu...rch/grand-challenge-award/how-to-apply?wssl=1
$20m sterling in non dilutive funding is nothing to be sneezed at even once shared - certainly more attractive than the A$750k that Bioshares felt was newsworthy. For me it would be the peer recognition from being awarded that would be more valuable than the cash itself. Many months to an announcement but if MYC is in the challenges then I assume we will put our hat in the ring for a partnership.
(20min delay)